Selected research
Market Structure
Global Glucagon Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Glucagon Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Glucagon Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Glucagon Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Glucagon Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Glucagon Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Glucagon Drug include Eli Lilly, Fresenius Kabi, Torrent Labs and Novo Nordisk, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Glucagon Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Glucagon Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Glucagon Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Glucagon Drug market size, projected growth trends, production technologies, key applications, and end-use industries.
Glucagon Drug Segment by Company
Eli Lilly
Fresenius Kabi
Torrent Labs
Novo Nordisk
Glucagon Drug Segment by Type
Inject Glucagon
Nasal Glucagon
Glucagon Drug Segment by Application
Cardiogenic Shock
General Use
Emergency Kits
Diagnostic & Motility
Others
Glucagon Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Glucagon Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Glucagon Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Glucagon Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Glucagon Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Glucagon Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Glucagon Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Glucagon Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Inject Glucagon
- Nasal Glucagon
Applications
- Cardiogenic Shock
- General Use
- Emergency Kits
- Diagnostic & Motility
- Others
Companies covered
- Eli Lilly
- Fresenius Kabi
- Torrent Labs
- Novo Nordisk
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Glucagon Drug Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Glucagon Drug Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Glucagon Drug Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Glucagon Drug Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Glucagon Drug Market Dynamics
- 2.1 Glucagon Drug Industry Trends
- 2.2 Glucagon Drug Industry Drivers
- 2.3 Glucagon Drug Industry Opportunities and Challenges
- 2.4 Glucagon Drug Industry Restraints
3 Glucagon Drug Market by Manufacturers
- 3.1 Global Glucagon Drug Revenue by Manufacturers (2021-2026)
- 3.2 Global Glucagon Drug Sales by Manufacturers (2021-2026)
- 3.3 Global Glucagon Drug Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Glucagon Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Glucagon Drug Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Glucagon Drug Manufacturers, Product Type & Application
- 3.7 Global Glucagon Drug Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Glucagon Drug Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Glucagon Drug Players Market Share by Revenue in 2025
- 3.8.3 2025 Glucagon Drug Tier 1, Tier 2, and Tier 3
4 Glucagon Drug Market by Type
- 4.1 Glucagon Drug Type Introduction
- 4.1.1 Inject Glucagon
- 4.1.2 Nasal Glucagon
- 4.2 Global Glucagon Drug Sales by Type
- 4.2.1 Global Glucagon Drug Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Glucagon Drug Sales by Type (2021-2032)
- 4.2.3 Global Glucagon Drug Sales Market Share by Type (2021-2032)
- 4.3 Global Glucagon Drug Revenue by Type
- 4.3.1 Global Glucagon Drug Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Glucagon Drug Revenue by Type (2021-2032)
- 4.3.3 Global Glucagon Drug Revenue Market Share by Type (2021-2032)
5 Glucagon Drug Market by Application
- 5.1 Glucagon Drug Application Introduction
- 5.1.1 Cardiogenic Shock
- 5.1.2 General Use
- 5.1.3 Emergency Kits
- 5.1.4 Diagnostic & Motility
- 5.1.5 Others
- 5.2 Global Glucagon Drug Sales by Application
- 5.2.1 Global Glucagon Drug Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Glucagon Drug Sales by Application (2021-2032)
- 5.2.3 Global Glucagon Drug Sales Market Share by Application (2021-2032)
- 5.3 Global Glucagon Drug Revenue by Application
- 5.3.1 Global Glucagon Drug Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Glucagon Drug Revenue by Application (2021-2032)
- 5.3.3 Global Glucagon Drug Revenue Market Share by Application (2021-2032)
6 Global Glucagon Drug Sales by Region
- 6.1 Global Glucagon Drug Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Glucagon Drug Sales by Region (2021-2032)
- 6.2.1 Global Glucagon Drug Sales by Region (2021-2026)
- 6.2.2 Global Glucagon Drug Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Glucagon Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Glucagon Drug Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Glucagon Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Glucagon Drug Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Glucagon Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Glucagon Drug Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Glucagon Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Glucagon Drug Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Glucagon Drug Revenue by Region
- 7.1 Global Glucagon Drug Revenue by Region
- 7.1.1 Global Glucagon Drug Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Glucagon Drug Revenue by Region (2021-2026)
- 7.1.3 Global Glucagon Drug Revenue by Region (2027-2032)
- 7.1.4 Global Glucagon Drug Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Glucagon Drug Revenue (2021-2032)
- 7.2.2 North America Glucagon Drug Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Glucagon Drug Revenue (2021-2032)
- 7.3.2 Europe Glucagon Drug Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Glucagon Drug Revenue (2021-2032)
- 7.4.2 Asia-Pacific Glucagon Drug Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Glucagon Drug Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Glucagon Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Eli Lilly
- 8.1.1 Eli Lilly Company Information
- 8.1.2 Eli Lilly Business Overview
- 8.1.3 Eli Lilly Glucagon Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Eli Lilly Glucagon Drug Product Portfolio
- 8.1.5 Eli Lilly Recent Developments
- 8.2 Fresenius Kabi
- 8.2.1 Fresenius Kabi Company Information
- 8.2.2 Fresenius Kabi Business Overview
- 8.2.3 Fresenius Kabi Glucagon Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Fresenius Kabi Glucagon Drug Product Portfolio
- 8.2.5 Fresenius Kabi Recent Developments
- 8.3 Torrent Labs
- 8.3.1 Torrent Labs Company Information
- 8.3.2 Torrent Labs Business Overview
- 8.3.3 Torrent Labs Glucagon Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Torrent Labs Glucagon Drug Product Portfolio
- 8.3.5 Torrent Labs Recent Developments
- 8.4 Novo Nordisk
- 8.4.1 Novo Nordisk Company Information
- 8.4.2 Novo Nordisk Business Overview
- 8.4.3 Novo Nordisk Glucagon Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Novo Nordisk Glucagon Drug Product Portfolio
- 8.4.5 Novo Nordisk Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Glucagon Drug Value Chain Analysis
- 9.1.1 Glucagon Drug Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Glucagon Drug Production Mode & Process
- 9.2 Glucagon Drug Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Glucagon Drug Distributors
- 9.2.3 Glucagon Drug Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst